Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Blazesbon Jun 12, 2020 12:40am

132 Views

Post# 31141761

RE:RE:Re: Partnership and/or Acquistion

It's not about individual purchases of pain meds. Recessions MAY stop pharmaceutical corporations from buying pain medication companies.

By raising 25 million AND shafting retail shareholders Antibe just demonstrated its determination to be the master of its own fate. They don't have to accept just any lowball offer.

According to Warren Buffet investing isn't like baseball. It's not three strikes and you're out. Antibe can stand in the batters box for as long as it wants before swinging at the offer it likes.

Bullboard Posts

Sirios Resource discovers visible gold in Quebec